Rubicon Organics Inc.

Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you.

Good morning, everyone. Welcome to Rubicon Organics Q4 2025 earnings call for the three and 12 months ended December 31st, 2025. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for analysts to queue up for questions. Before we begin, please refer to slide two for our caution regarding forward-looking statements and non-GAAP measures. Today's presenters are Margaret Brody, CEO, and Glenn Ibbitt, CFO. I will now turn the call over to Margaret.

Thank you, and good morning, everyone from Vancouver. I'm pleased to share our 2025 results and provide an update on our strategy for significant revenue and EBITDA growth in 2026. 2025 was a transformational year for Rubicon as Canada's number one premium licensed producer. We achieved record financial performance, growing revenue by 22% and adjusted EBITDA by 25% despite our constrained capacity and scale-up investments. We swiftly operationalized the newly acquired, highly accretive Cascadia facility. This purpose-built facility will increase our existing cultivation capacity output by at least 40% and unlock our ability to service the large, unmet demand for our nationally leading brand portfolio. In 2025, we had made significant progress on our international strategy, and we are now ready to execute our branded strategic entry. We also advanced several other critical projects that will begin delivering further growth and operating leverage in 2026. Before Glenn takes you through the financial results, I want to again emphasize our focus in optimizing our existing operational profile and facilities and driving further leverage into our 2026 revenue, margin, and operating cash flow.